N@N

Patient Home Monitoring announces agreement to use in-home coagulation monitoring software application from Standing Stone as i

^{Published on 2010-06-25 09:11:32 - Market Wire}
 

SAN FRANCISCO, CA, June 25 /CNW/ - Patient Home Monitoring (PHM) (TSXV:PHM), a company focused on in-home cardiology healthcare services, today announced an agreement to use Standing Stone, Inc.'s in-home coagulation monitoring software application, a module of CoagClinic, as its platform for monitoring patients on Coumadin and other anti-coagulants.

Standing Stone's CoagClinic coagulation management software is used by hundreds of laboratory and physician clients nationwide which manage hundreds of thousands of patients on anti-coagulants. Standing Stone is the leading supplier of secure, web-based applications that provide decision support tools to health care professionals engaged in disease state management.

"CoagClinic is a leading application used to manage patients by many large cardiology groups and laboratories. Using the CoagClinic in-home module as a platform gives PHM an industry leading application which is familiar to many of our potential clients," said Michael Dalsin, Chairman of Patient Home Monitoring. "PHM is focused on providing a high level of service to patients and physicians in an efficient and cost effective manner. As part of completing the launch phase of the business, PHM continues to add the necessary tools to build a world class business."

Additionally, in reviewing PHM's launch of the business, it has been determined that Michael Dalsin will serve as interim Chief Financial Officer rather than Ed Berenblum.

About PHM

PHM is a healthcare services company focused on providing in-home testing for patients on blood thinner medications such as Coumadin or warfarin. Medicare recently expanded reimbursement for in-home patient self testing (PST) of blood coagulation levels. PHM has a unique value proposition to cardiology groups that manage patients on blood thinners, focusing on systemization of enrolling patients in PST. This unique, systemized approach creates an opportunity for physician groups to operate more efficiently, while providing a higher standard of care for patients.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

%SEDAR: 00008298E